



Published in final edited form as:

J Sleep Res. 2021 December ; 30(6): e13392. doi:10.1111/jsr.13392.

Associations between sleep disturbances, diabetes and mortality in the UK Biobank cohort: a prospective population-based study

Malcolm von Schantz¹, Jason C. Ong², Kristen L. Knutson²

¹Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK

²Center for Circadian and Sleep Medicine, Department of Neurology, Northwestern University, 710 N Lakeshore Dr, Chicago IL USA

Summary

Non-communicable diseases, including diabetes, are partly responsible for the deceleration of life expectancy improvements in many countries. Diabetes is also associated with sleep disturbances. Our aim was to determine whether sleep disturbances, particularly in people with diabetes, were associated with increased mortality risk. Data from UK Biobank were analysed (n=487,728, mean follow-up time: 8.9 years). Primary exposure was sleep disturbances, assessed through the question “Do you have trouble falling asleep at night or do you wake up in the middle of the night?”. Primary outcome was mortality. We also dichotomized sleep disturbances into “never/sometimes” vs “usually” (frequent) and combined with presence/absence of diabetes. 24.2% of participants reported “never/rarely” experiencing sleep disturbances, 47.8% “sometimes” and 28.0% “usually”. In age- and sex-adjusted models, frequent sleep disturbances were associated with increased risk of all-cause mortality (HR 1.31, 95% CI 1.26-1.37), which remained significant in the fully-adjusted model (HR 1.13, 95% CI 1.09-1.18). Presence of both diabetes and frequent sleep disturbances was associated with greater risk of all-cause mortality than either condition alone. In the fully adjusted model, the hazard ratio for all-cause mortality was 1.11 (95% CI 1.07-1.15) for frequent sleep disturbances alone, 1.67 (95% CI 1.57-1.76) for diabetes alone and 1.87 for both (95% CI 1.75-2.01). Frequent sleep disturbances (experienced by more than one quarter of the sample) were associated with increased risk of all-cause mortality. Mortality risk was highest in those with both diabetes and frequent sleep disturbances. Complaints of difficulty falling or staying asleep merit attention by physicians.

Keywords

Cohort study; Diabetes mellitus; Insomnia; Non-communicable disease; Sleep Disorders

Corresponding Author: Kristen L. Knutson, PhD, Center for Circadian and Sleep Medicine, Department of Neurology, Northwestern University Feinberg School of Medicine, 710 N Lakeshore Drive, Room 523, Chicago, IL 60611, Tel: 312-503-1526, Fax: 312-503-5679, kristen.knutson@northwestern.edu.

Author contributions: KLK & MvS designed the study, KLK analysed the data, KLK, MvS & JCO wrote the paper.

Conflict of interests: MvS: none, JCO: none, KLK: none

INTRODUCTION

Increases in life expectancy have slowed or even ceased in the United States, the United Kingdom and comparable countries (Murphy et al., 2018, Office for National Statistics, 2018). In the majority of countries, people have a high risk of premature mortality due to non-communicable diseases (NCD), including diabetes, than other conditions (NCD Countdown 2030 collaborators, 2018). The mortality rates due to these non-communicable diseases (NCD) are expected to increase by approximately 54% between 2016 and 2040, and deaths due specifically to type 2 diabetes are estimated to more than double worldwide (Foreman et al., 2018). Indeed, diabetes increases the risk of all-cause and cardiovascular mortality (Haffner et al., 1998). An international group led by the U.N. set a goal to reduce by one-third the rates of premature mortality due to NCD by the year 2030, but only 16% of countries are on target for men and 19% of countries are on target for women (NCD Countdown 2030 collaborators, 2018). Given that NCDs are the leading causes of death and the rates of premature mortality rates are not declining as targeted, it is important to gain a greater understanding of the underlying causes of NCD-associated mortality. Here, we have used data from the UK Biobank to examine the effect of sleep disturbances and their interactions with diabetes, a major NCD, on morbidity and mortality.

Diabetes and early mortality have both been associated with inadequate sleep, including insufficient duration or poor quality of sleep (e.g. (Tamakoshi and Ohno, 2004, Heslop et al., 2002, Hublin et al., 2007, Kripke et al., 2011, Akerstedt et al., 2017, Anothaisintawee et al., 2016). A number of studies have examined sleep disturbances or insomnia complaints in relation to mortality risk, and some observed significantly increased risk of mortality associated with these sleep-related complaints (Sivertsen et al., 2014, Li et al., 2014), while others did not (Althuis et al., 1998, Kripke et al., 2002, Rockwood et al., 2001, Lovato and Lack, 2019). This discrepancy could be due to differences in the demographics of the sample, as ages and proportions of men and women varied among studies, as did sociodemographic and cultural factors. People with diabetes generally have poorer sleep quality (Trento et al., 2008) and poorer sleep quality has been associated with worse glycemic control (Knutson et al., 2006, Knutson et al., 2011). Whether the combination of diabetes and frequent sleep disturbances affects mortality risk has not been previously reported.

The aims of the analyses presented here were to determine whether sleep disturbances were associated with increased risk of all-cause and cardiovascular disease (CVD) mortality in a large study of adults in the UK and to determine whether having both frequent sleep disturbances and diabetes was more strongly associated with mortality than either condition on its own. We hypothesised that frequent sleep disturbances would be associated with increased mortality risk, particularly in those with diabetes.

METHODS

We used data from the UK Biobank, which is a large, prospective, population-based cohort study designed to investigate risk factors for major disease of middle and older age (Sudlow et al., 2015). It enrolled 502,642 people aged 37-73 years (53% women) from across the UK

between March 2006 and October 2010. The study invited every individual within this age range who was registered with the National Health Service and living up to about 25 miles from an assessment centre to participate (Allen et al., 2012). Identical assessment procedures were used across field sites. For the analyses presented here, we have death records up to February 14, 2018, which provided a mean follow-up time of 8.9 years (range 4 days to 11.9 years) among its participants and 98% of deaths occurred after 6 months of follow-up. The UK Biobank protocol is available online (Palmer, 2007).

The primary exposure variable was the presence of sleep disturbances, as assessed through a single question that asked, “Do you have trouble falling asleep at night or do you wake up in the middle of the night?” with the three response options, “never/rarely”, “sometimes”, “usually”. Only 0.1% of participants did not answer this question.

The primary outcome was mortality, including all-cause mortality and mortality due to cardiovascular disease (CVD). Mortality information was obtained from the National Health Service for England and Wales and the NHS Central Register in Scotland. All details from the death certificate were provided to UK Biobank personnel, who coded primary cause of death according to ICD10. We classified the ICD10 codes I00-I99 as CVD-related mortality. If no death was recorded for a participant, they were assumed to still be living.

We examined the interaction between the presence of sleep disturbances and the presence of diabetes. Participants were classified as having diabetes if they reported a previous diagnosis of diabetes or they reported taking insulin. We dichotomized sleep disturbances into “never”/“sometimes” (infrequently) vs “usually” (frequently) and combined this with presence/absence of diabetes to create four groups. We also created six groups based on three levels of sleep disturbance frequency and presence of diabetes.

Covariates included age, sex, ethnicity, socioeconomic deprivation, smoking, sleep duration, body mass index (BMI), and comorbidities. Age was calculated based on date of birth and date of examination. Sex was acquired from the central registry and updated by participant, if needed. Ethnicity was self-identified and the majority of the sample (94%) described themselves as “white”. Therefore, we dichotomized ethnicity into “white” and “non-white”. The measure of socioeconomic deprivation was based on the Townsend deprivation index (Townsend et al., 1988), which summarises deprivation of a postcode based on the rates of unemployment, absence of ownership of car and home, and household overcrowding. Smoking status was obtained by self-report with the following categories: “never”, “previous smoker”, “current smoker”, and “prefer not to answer”. Sleep duration was based on the question, “About how many hours sleep do you get in every 24 hours (please include naps)?” and responses were provided as integers. Standing height was measured using a Seca 240-cm height measure while participants stood barefoot with posture verified by trained staff. Weight was measured using a Tanita BC418MA body composition analyser and BMI (kg/m^2) was calculated. Comorbidities were recorded based on self-report during an interview by a trained nurse and are all comorbidity variables are dichotomous (present/absent). We used the codes provided by the UK Biobank to classify them into the following 11 comorbidity variables for analyses (see Supplemental Table 1 for complete list of codes): cardiovascular disease, diabetes, other endocrine disorders, neurological disorders,

renal disorders respiratory disorders, musculoskeletal disorders, gastrointestinal/abdominal disorders, depression, other psychological disorders and cancer. A participant only needed a report of one code to be classified as having that comorbidity. Each comorbidity was treated as a separate variable in the analyses.

Insomnia symptom data were missing for 1,504 participants, 9,705 participants were missing BMI, 3,000 were missing sleep duration, 603 were missing the Townsend index and 3 participants had a negative follow-up period, resulting in a final sample size of 487,728 participants. Means and standard deviations (SD) or proportions (%) were calculated to describe the sample. Cox proportional hazards models were estimated to determine associations with all-cause and CVD mortality. There were two models, one adjusting for age and sex only and one adjusting for all covariates. Further, we examined sleep disturbances alone (“never/rarely” was referent) as well as the four or six groups based on frequency of sleep disturbances and diabetes (absence of both was referent). In addition, to determine whether the two groups with diabetes differed, we repeated the analysis with the four groups using the diabetes alone group as the referent. Finally, we tested an interaction term between diabetes and sleep disturbances to determine whether the association between sleep disturbances and mortality risk varied between those with and without diabetes. All statistical analyses were performed using Stata, v14 (Statacorp, College Station, TX).

RESULTS

Table 1 describes the sample in full as well as stratified by sleep disturbances. Approximately one quarter of the sample reported “never/rarely” experiencing sleep disturbances, 47.8% answered “sometimes”, and 28.0% answered “usually”. On average, those who reported frequent sleep disturbances were older, had a higher BMI, slept less, and were more likely to be female, white, current smokers, and have depression and diabetes. Approximately 69% of the sample had neither diabetes nor frequent sleep disturbances, 26% had frequent sleep disturbances but not diabetes, 3% had diabetes but not frequent sleep disturbances and 2% had both. During the mean follow-up period of 8.9 years, there were 19,177 deaths from all causes and 3,874 deaths from CVD.

Frequent sleep disturbances were significantly associated with all-cause mortality (Figure 1). In age- and sex-adjusted models, frequent sleep disturbances were associated with increased risk of all-cause mortality (HR 1.31, 95% CI 1.26-1.37), which remained significant in the fully-adjusted model (HR 1.13, 95% CI 1.09-1.18). Frequent sleep disturbances were significantly associated with increased risk of CVD mortality in the age- and sex-adjusted models (HR 1.33, 95% CI 1.22-1.44) but this association did not remain significant in the fully adjusted models (HR 1.02, 95% CI 0.93-1.12).

The analysis of sleep disturbances and diabetes demonstrated that the presence of either frequent sleep disturbances or diabetes was associated with increased risk of all-cause mortality compared to those who had neither condition (Figure 1). In the fully adjusted model, the hazard ratio for all-cause mortality was 1.11 (95% CI 1.07-1.15) for frequent sleep disturbances alone, 1.67 (95% CI 1.57-1.76) for diabetes alone and 1.87 for both (95% CI 1.75-2.01). In addition, the group who had both frequent sleep disturbances and

diabetes demonstrated a greater risk of all-cause mortality compared to those with only diabetes (HR 1.12, 95% CI 1.04-1.22). Both groups with diabetes had an increased risk of CVD mortality compared to those with neither frequent sleep disturbances nor diabetes. In fully adjusted models, the HR was 2.04 (95% CI 1.84-2.27) for diabetes alone and 2.11 (95% CI 1.85-2.40) for both. There was no significant difference in risk of CVD mortality between the two diabetes groups (HR 1.03, 95% CI 0.89-1.20 for both frequent insomnia and diabetes compared to diabetes alone). The interaction between sleep disturbances and diabetes was not significant in either the model predicting all-cause mortality ($p=.40$) or in the model predicting CVD mortality ($p=.68$), which indicates the association between sleep disturbances and mortality did not differ between those with and without diabetes. In analyses that created six groups based on diabetes and three levels of sleep disturbances (Supplemental Table 2), similar associations were observed. In the fully adjusted models, the group without diabetes but frequent sleep disturbances and all three groups with diabetes had an increased risk of all-cause mortality compared to the group with neither diabetes nor sleep disturbances.

DISCUSSION

In this large, UK-based population study, we observed significant associations between frequent sleep disturbances and all-cause mortality risk. Frequent sleep disturbances were experienced by more than one quarter of the sample, and thus is highly prevalent in the UK, which is consistent with other observational studies (Ohayon, 2002). In addition, individuals with diabetes who also experienced frequent sleep disturbances had a greater risk of mortality than those with diabetes who did not report frequent sleep disturbances. Further the association between frequent sleep disturbances and mortality risk did not differ between those who did and did not have diabetes.

Our findings from this UK cohort are consistent with studies from other countries. A study from Norway assessed self-reported insomnia in adults 40-45 years at baseline and followed them for 13-15 years. They reported that insomnia at baseline was a significant predictor of all-cause mortality (HR = 3.34, 95% CI:1.67-6.69) (Sivertsen et al., 2014). A large study of middle-aged and older men in the US also reported difficulty initiating sleep (HR:1.55; 95% CI:1.19-2.04) and non-restorative sleep (HR:1.32; 95% CI:1.02-1.72) were associated with increased risk of all-cause mortality (Li et al., 2014). A Chinese study observed that adults who reported sleep disturbances nearly every day had an increased risk of mortality over approximately 16 years (Chien et al., 2010). A community-based prospective study in the U.S. with a 20-year follow-up found that persistent insomnia (reporting symptoms at two assessments) was associated with increased mortality risk, however, reporting sleep disturbances at only one assessment was not (Parthasarathy et al., 2015). Not all studies that examined indicators of insomnia observed significant associations with mortality risk (Kripke et al., 2002, Althuis et al., 1998, Rockwood et al., 2001, Lovato and Lack, 2019). The discrepant findings could be due to differences in insomnia assessment, characteristics of the population studied or covariate adjustment, including comorbidities.

Sleep disturbances have been associated with cardiovascular disease in prior research. For example, one prospective population-based study from Norway followed participants for

approximately 11 years and found that risk of acute myocardial infarction was significantly higher for individuals who had difficulty falling asleep almost every night (HR = 1.45, 95% CI: 1.18 – 1.80) and for individuals who had difficulties maintaining sleep almost every night (HR = 1.30, 95% CI: 1.01 – 1.68) compared to those who never have these sleep difficulties (Laugsand et al., 2011). The same study also observed a significant increased risk of heart failure among those who had difficulty falling asleep almost every night (HR = 1.32, 95% CI: 1.01 – 1.72) compared to those who never have these sleep difficulties (Laugsand et al., 2014). A large population-based study in Taiwan also observed a significant increased risk of acute myocardial infarction, as well as stroke, among people with diagnosed insomnia (Hsu et al., 2015). In our study, however, we did not observe a significant association between frequent sleep disturbances and cardiovascular disease mortality during the 8.9 year follow-up period. This may be because mortality from CVD is not impacted by sleep disturbances (at least as defined by the single question used here or limited power due to lower number of CVD deaths).

To our knowledge, this is the first study to examine the effect of the combination of insomnia and diabetes on mortality risk. Diabetes has been previously associated with increased risk of cardiovascular disease and mortality (Stamler et al., 1993, Haffner et al., 1998), and diabetes has been associated with impaired sleep. Several studies have found a strong association between obstructive sleep apnoea (OSA) and type 2 diabetes (Huang et al., 2018, Subramanian et al., 2019), and OSA impairs sleep quality. Further, some observational studies have found that among people with type 2 diabetes, worse sleep quality is associated with higher haemoglobin A1c, suggesting poorer glycemic control (Knutson et al., 2006, Knutson et al., 2011). A meta-analysis of 9 studies among adults with type 2 diabetes also found that poor sleep quality was associated with higher haemoglobin A1c (Lee et al., 2017), and insomnia has been identified as a risk factor for type 2 diabetes both in observational (Vgontzas et al., 2009) and Mendelian randomization studies (Yuan and Larsson, 2020). Experimental studies that impaired sleep quality did observe impairments in glucose regulation in healthy volunteers (Tasali et al., 2008, Stamatakis and Punjabi, 2010). If chronic poor sleep quality due to a sleep disorder can impair glucose control in people with diabetes, then this could be a mechanism leading to the increased risk of mortality in people with diabetes and frequent sleep disturbances.

The strengths of this study include the large sample size and the prospective monitoring of mortality. The UK Biobank study aimed to assemble a general population sample — however, this cohort does appear to be slightly healthier on average than the general UK population (Fry et al., 2017), which may limit generalizability somewhat. We also do not have access to measures of hypnotic or alcohol use in our dataset and these could be important confounders or mediators of the association between sleep disturbances and mortality. Another limitation is that the mean follow-up time is only 8.9 years and a longer period would result in a higher number of mortalities, which could increase power for the CVD mortality analyses. Finally, sleep disturbances are based on a single self-reported question, which did not assess daytime consequences, and is not equivalent to a clinically diagnosed insomnia disorder. However, this same question in the same sample has recently been used successfully for genome-wide association studies (Lane et al., 2016, Jansen et al., 2019), with the most significant hits being replicated both in a sub-stratification of the UK

Biobank study based on accelerometry and in a separate insomnia cohort (Lane et al., 2016). In addition, people who endorse sleep disturbances are likely a heterogeneous group with respect to the underlying pathology. Further, these data do not include objective measures of sleep quality, sleep duration or sleep-disordered breathing so we cannot identify sub-types of insomnia or other sleep disorders. The data presented here suggest that regardless of the cause of the sleep disturbance, endorsing sleep disturbances on a frequent basis is an important signal of elevated risk of mortality. Such symptoms should therefore be investigated further by physicians, particularly in patients who have also been diagnosed with diabetes. Follow-up instruments, such as the insomnia severity index (ISI), have the potential to further refine the understanding of the nature of the complaint and could feasibly be included in larger cohort studies.

Since a large proportion of the sample reported frequent sleep disturbances (28%), these findings have important public health implications. The results are also relevant to clinical practice and frequent sleep disturbances may be an important health indicator for clinicians to consider, particularly for diabetes patients. We found that a single question was sufficient to detect mortality risk and clinicians could use a similar, brief question to identify patients who may need additional therapy or support.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS


This work was partially supported by funding from the US National Institutes of Health (R01DK095207, 1R01HL141881) (to KLK and MvS) and by a University of Surrey Institute of Advanced Studies Santander fellowship (to KLK).

REFERENCES

- Akerstedt T, Ghilotti F, Grotta A, Bellavia A, Lagerros YT and Bellocco R Sleep duration, mortality and the influence of age. *Eur. J. Epidemiol*, 2017, 32: 881–91. [PubMed: 28856478]
- Allen N, Sudlow C, Downey P et al. UK Biobank: Current status and what it means for epidemiology. *Health Policy Techn*, 2012, 1: 123–26.
- Althuis MD, Fredman L, Langenberg PW and Magaziner J The relationship between insomnia and mortality among community-dwelling older women. *J. Am. Geriatr. Soc*, 1998, 46: 1270–3. [PubMed: 9777910]
- Anothaisintawee T, Reutrakul S, Van Cauter E and Thakkinstian A Sleep disturbances compared to traditional risk factors for diabetes development: Systematic review and meta-analysis. *Sleep Med Rev*, 2016, 30: 11–24. [PubMed: 26687279]
- Chien KL, Chen PC, Hsu HC et al. Habitual sleep duration and insomnia and the risk of cardiovascular events and all-cause death: report from a community-based cohort. *Sleep*, 2010, 33: 177–84. [PubMed: 20175401]
- Foreman KJ, Marquez N, Dolgert A et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. *Lancet*, 2018, 392: 2052–90. [PubMed: 30340847]
- Fry A, Littlejohns TJ, Sudlow C et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants with the General Population. *Am. J. Epidemiol*, 2017

- Haffner SM, Lehto S, Ronnema T, Pyorala K and Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N. Engl. J. Med.*, 1998, 339: 229–34. [PubMed: 9673301]
- Heslop P, Smith G, Metcalfe C, Macleod J and Hart C Sleep duration and mortality: the effect of short or long sleep duration on cardiovascular and all-cause mortality in working men and women. *Sleep Medicine*, 2002, 3: 305–14. [PubMed: 14592192]
- Hsu CY, Chen YT, Chen MH et al. The Association Between Insomnia and Increased Future Cardiovascular Events: A Nationwide Population-Based Study. *Psychosom. Med.*, 2015, 77: 743–51. [PubMed: 26355726]
- Huang T, Lin BM, Stampfer MJ, Tworoger SS, Hu FB and Redline S A Population-Based Study of the Bidirectional Association Between Obstructive Sleep Apnea and Type 2 Diabetes in Three Prospective U.S. Cohorts. *Diabetes Care*, 2018, 41: 2111–19. [PubMed: 30072403]
- Hublin C, Partinen M, Koskenvuo M and Kaprio J Sleep and mortality: a population-based 22-year follow-up study. *Sleep*, 2007, 30: 1245–53. [PubMed: 17969458]
- Jansen PR, Watanabe K, Stringer S et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. *Nat. Genet.*, 2019, 51: 394–403. [PubMed: 30804565]
- Knutson KL, Ryden AM, Mander BA and Van Cauter E Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. *Arch. Intern. Med.*, 2006, 166: 1768–74. [PubMed: 16983057]
- Knutson KL, Van Cauter E, Zee P, Liu K and Lauderdale DS Cross-sectional associations between measures of sleep and markers of glucose metabolism among subjects with and without diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Sleep Study. *Diabetes Care*, 2011, 34: 1171–6. [PubMed: 21411507]
- Kripke DF, Garfinkel L, Wingard DL, Klauber MR and Marler MR Mortality associated with sleep duration and insomnia. *Arch. Gen. Psychiatry*, 2002, 59: 131–6. [PubMed: 11825133]
- Kripke DF, Langer RD, Elliott JA, Klauber MR and Rex KM Mortality related to actigraphic long and short sleep. *Sleep Med*, 2011, 12: 28–33. [PubMed: 20870457]
- Lane JM, Vlasac I, Anderson SG et al. Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank. *Nat Commun*, 2016, 7: 10889. [PubMed: 26955885]
- Laugsand LE, Strand LB, Platou C, Vatten LJ and Janszky I Insomnia and the risk of incident heart failure: a population study. *Eur. Heart J*, 2014, 35: 1382–93. [PubMed: 23462728]
- Laugsand LE, Vatten LJ, Platou C and Janszky I Insomnia and the risk of acute myocardial infarction: a population study. *Circulation*, 2011, 124: 2073–81. [PubMed: 22025601]
- Lee SWH, Ng KY and Chin WK The impact of sleep amount and sleep quality on glycemetic control in type 2 diabetes: A systematic review and meta-analysis. *Sleep Med Rev*, 2017, 31: 91–101. [PubMed: 26944909]
- Li Y, Zhang X, Winkelman JW et al. Association between insomnia symptoms and mortality: a prospective study of U.S. men. *Circulation*, 2014, 129: 737–46. [PubMed: 24226807]
- Lovato N and Lack L Insomnia and mortality: A meta-analysis. *Sleep Med Rev*, 2019, 43: 71–83. [PubMed: 30529432]
- Murphy SL, Xu J, Kochanek KD and Arias E Mortality in the United States, 2017. *NCHS Data Brief*, 2018: 1–8.
- Ncd Countdown 2030 Collaborators NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. *Lancet*, 2018, 392: 1072–88. [PubMed: 30264707]
- Office for National Statistics Changing trends in mortality: an international comparison: 2000 to 2016. In. Office for National Statistics, London, United Kingdom, 2018.
- Ohayon MM Epidemiology of insomnia: what we know and what we still need to learn. *Sleep Med Rev*, 2002, 6: 97–111. [PubMed: 12531146]
- Palmer LJ UK Biobank: bank on it. *Lancet*, 2007, 369: 1980–82. [PubMed: 17574079]
- Parthasarathy S, Vasquez MM, Halonen M et al. Persistent insomnia is associated with mortality risk. *Am. J. Med.*, 2015, 128: 268–75 e2. [PubMed: 25447616]

- Rockwood K, Davis HS, Merry HR, Macknight C and McDowell I Sleep disturbances and mortality: results from the Canadian Study of Health and Aging. *J. Am. Geriatr. Soc.*, 2001, 49: 639–41. [PubMed: 11380758]
- Sivertsen B, Pallesen S, Glozier N et al. Midlife insomnia and subsequent mortality: the Hordaland health study. *BMC Public Health*, 2014, 14: 720. [PubMed: 25024049]
- Stamatakis KA and Punjabi NM Effects of sleep fragmentation on glucose metabolism in normal subjects. *Chest*, 2010, 137: 95–101. [PubMed: 19542260]
- Stamler J, Vaccaro O, Neaton JD and Wentworth D Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care*, 1993, 16: 434–44. [PubMed: 8432214]
- Subramanian A, Adderley NJ, Tracy A et al. Risk of Incident Obstructive Sleep Apnea Among Patients With Type 2 Diabetes. *Diabetes Care*, 2019, 42: 954–63. [PubMed: 30862657]
- Sudlow C, Gallacher J, Allen N et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*, 2015, 12: e1001779. [PubMed: 25826379]
- Tamakoshi A and Ohno Y Self-Reported Sleep Duration as a Predictor of All-Cause Mortality: Results from the JACC Study, Japan. *Sleep*, 2004, 27: 51–54. [PubMed: 14998237]
- Tasali E, Leproult R, Ehrmann DA and Van Cauter E Slow-wave sleep and the risk of type 2 diabetes in humans. *Proc. Natl. Acad. Sci. U. S. A.*, 2008, 105: 1044–9. [PubMed: 18172212]
- Townsend P, Phillimore P and Beattie A Health and deprivation : inequality and the North. Croom Helm, London ; New York, 1988 (
- Trento M, Broglio F, Riganti F et al. Sleep abnormalities in type 2 diabetes may be associated with glycemic control. *Acta Diabetol*, 2008, 45: 225–9. [PubMed: 18685806]
- Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M and Bixler EO Insomnia with objective short sleep duration is associated with type 2 diabetes: A population-based study. *Diabetes Care*, 2009, 32: 1980–5. [PubMed: 19641160]
- Wickwire EM, Tom SE, Vadlamani A et al. Older adult US Medicare beneficiaries with untreated obstructive sleep apnea are heavier users of health care than matched control patients. *J Clin Sleep Med*, 2020, 16: 81–89. [PubMed: 31957657]
- Yuan S and Larsson SC An atlas on risk factors for type 2 diabetes: a wide-angled Mendelian randomisation study. *Diabetologia*, 2020, 63: 2359–71. [PubMed: 32895727]



Abbreviations: Diab – Diabetes; Insom - Insomnia

Figure 1. Hazard ratios (95% CI) for mortality for sleep disturbances and for diabetes and insomnia groups. Panel A: Age- and sex- adjusted hazard ratios for all-cause mortality. Panel B: Fully adjusted hazard ratios for all-cause mortality. Panel C: Age- and sex- adjusted hazard ratios for CVD mortality. Panel D: Fully adjusted hazard ratios for CVD mortality. Fully-adjusted models included the following covariates: age, sex, race, smoking status, BMI, sleep duration, Townsend deprivation index, and all comorbidities (CVD, diabetes, other endocrine disorders, neurological disorders, renal disorders, respiratory disorders, musculoskeletal disorders, gastrointestinal disorders, depression, other psychological disorders and cancer).

Table 1.

Description of full sample and by insomnia symptom frequency.

	Full Sample	Sleep disturbances		
		Never/rarely	Sometimes	Usually
N	487,728	118,217 (24.2%)	233,177 (47.8%)	136,334 (28.0%)
Age (years) †	56.5 (8.1)	55.2 (8.4)	56.6 (8.1)	57.5 (7.7)
Female †	54.4%	42.5%	56.3%	61.7%
White Ethnicity †	94.4%	93.6%	94.2%	95.5%
Smoking Status †				
Never	54.6%	57.1%	55.4%	51.1%
Previous	34.6%	32.3%	34.1%	37.3%
Current	10.5%	10.3%	10.1%	11.3%
Depression †	5.6%	3.3%	5.2%	8.2%
Diabetes †	5.0%	4.4%	4.6%	6.3%
BMI (kg/m ²) †	27.4 (4.8)	27.2 (4.5)	27.3 (4.7)	27.9 (5.1)
Sleep Duration (h) †	7.2 (1.1)	7.4 (1.0)	7.3 (1.0)	6.7 (1.3)

Mean (standard deviation) for continuous variables; % for categorical

BMI: Body Mass Index

†p<0.01 comparing insomnia symptom groups based on ANOVA (continuous variables) or Chi Square (Categorical variables)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript